Rye Brook Capital’s Novo Nordisk NVO Stock Holding History

Rye Brook Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-6,500	Closed	-$312K	–	43
2026 Q2	$312K	Buy	+6,500	New	+$279K	0.22%	33

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Everett Harris & Co Los Angeles, California $8.46B AUM 13.48% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $142B AUM 43.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Rye Brook Capital's NVO Position: Q3 2026 in Review

Rye Brook Capital sold out of Novo Nordisk (NVO) in Q3 2026, closing a stake of 6,500 shares — an estimated $312K sold.

Rye Brook Capital first reported a position in NVO in Q2 2026 and held it in 1 quarter. The position peaked at $312K in Q2 2026. 921 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

Rye Brook Capital reported no remaining Novo Nordisk position as of Q3 2026 after selling out during the quarter.
Rye Brook Capital sold 6,500 Novo Nordisk shares in Q3 2026, an estimated $312K.
Rye Brook Capital first reported a position in Novo Nordisk in Q2 2026 and held it in 1 quarter.
Rye Brook Capital's Novo Nordisk position peaked at $312K in Q2 2026.
921 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Rye Brook Capital's 13F filing for Q3 2026, filed 7 Oct 2026.